- Home
- TEI vs LRMR Comparison
TEI vs LRMR Comparison
Compare TEI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | LRMR |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.2M | 280.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TEI | LRMR |
|---|---|---|
| Price | $6.98 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 142.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $1.61 |
| 52 Week High | $5.39 | $5.37 |
Technical Indicators
Market Signals| Indicator | TEI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 73.76 | 40.26 |
| Support Level | $6.69 | $3.06 |
| Resistance Level | $6.95 | $3.40 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 97.37 | 12.86 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.